Amalgamated Bank Celldex Therapeutics, Inc. Transaction History

Amalgamated Bank

$12.1 Billion
Q3 2024

A detailed history of Amalgamated Bank transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 2,182 shares of CLDX stock, worth $57,168. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,182

Previous 2,182 -0.0%

Holding current value

$57,168

Previous $81,000 8.64%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$32.76 - $42.56 $3,144 - $4,085	96 Added 4.6%	2,182 $81,000
Q1 2024 Apr 23, 2024	SELL	$35.22 - $51.88 $92,276 - $135,925	-2,620 Reduced 55.67%	2,086 $88,000
Q4 2023 Feb 06, 2024	SELL	$22.61 - $40.65 $10,558 - $18,983	-467 Reduced 9.03%	4,706 $187,000
Q2 2023 Aug 11, 2023	SELL	$30.29 - $38.28 $636 - $803	-21 Reduced 0.4%	5,173 $175,000
Q1 2023 May 02, 2023	SELL	$34.78 - $47.43 $36,519 - $49,801	-1,050 Reduced 16.82%	5,194 $187,000
Q4 2022 Feb 10, 2023	BUY	$27.78 - $45.38 $1,777 - $2,904	64 Added 1.04%	6,244 $278,000
Q3 2022 Nov 09, 2022	BUY	$22.7 - $37.57 $1,566 - $2,592	69 Added 1.13%	6,180 $174,000
Q2 2022 Aug 15, 2022	SELL	$20.5 - $37.33 $19,864 - $36,172	-969 Reduced 13.69%	6,111 $165,000
Q1 2022 Jun 30, 2022	SELL	$27.64 - $39.32 $15,367 - $21,861	-556 Reduced 7.28%	7,080 $241,000
Q4 2021 Feb 15, 2022	SELL	$35.68 - $56.27 $2,461 - $3,882	-69 Reduced 0.9%	7,636 $295,000
Q3 2021 Oct 29, 2021	BUY	$28.95 - $55.99 $20,380 - $39,416	704 Added 10.06%	7,705 $416,000
Q2 2021 Aug 16, 2021	BUY	$20.71 - $35.37 $144,990 - $247,625	7,001 New	7,001 $234,000

Others Institutions Holding CLDX

# of Institutions

207

Shares Held

67.3M

Call Options Held

1.69M

Put Options Held

980K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.23B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account

Amalgamated Bank Celldex Therapeutics, Inc. Transaction History